Below are the most recent publications written about "Pharmacovigilance" by people in Profiles.
-
de Leon J, Baldessarini RJ, Balon R, Bilbily J, Caroff SN, Citrome L, Correll CU, Cotes RO, Davis JM, DeLisi LE, Faden J, Freudenreich O, Goldsmith DR, Gurrera R, Josiassen RC, Kane JM, Kelly DL, Keshavan MS, Laitman RS, Lam YWF, Leung JG, Love RC, McCollum B, McGrane IR, Meyer JM, Nasrallah HA, Nucifora FC, Rothschild AJ, Rubio JM, Sajatovic M, Sarpal DK, Schoretsanitis G, Shad M, Shelton C, Sher L, Singh B, Surya S, Zarzar TR, Sanz EJ, De Las Cuevas C. Letter to the FDA Proposing Major Changes in the US Clozapine Package Insert Supported by Clozapine Experts Worldwide. Part II: A Review of Fatal Outcomes in US Pharmacovigilance Data and Proposed Changes. J Clin Psychopharmacol. 2025 May-Jun 01; 45(3):197-218.
-
de Leon J, Baldessarini RJ, Balon R, Bilbily J, Caroff SN, Citrome L, Correll CU, Cotes RO, Davis JM, DeLisi LE, Faden J, Freudenreich O, Goldsmith DR, Gurrera R, Josiassen RC, Kane JM, Kelly DL, Keshavan MS, Laitman RS, Lam YWF, Leung JG, Love RC, McCollum B, McGrane IR, Meyer J, Nasrallah HA, Nucifora FC, Rothschild AJ, Rubio JM, Sajatovic M, Sarpal DK, Schoretsanitis G, Shad M, Shelton C, Sher L, Singh B, Surya S, Zarzar TR, Sanz EJ, De Las Cuevas C. Letter to the FDA Proposing Major Changes in the US Clozapine Package Insert Supported by Clozapine Experts Worldwide. Part I: A Review of the Pharmacokinetic Literature and Proposed Changes. J Clin Psychopharmacol. 2025 May-Jun 01; 45(3):179-196.
-
Nakhla M, Nair A, Balani P, Ujjawal A, Arun Kumar P, Dasari M, Yukselen Z, Bansal K, Ganatra S, Dani SS. Risk of Suicide, Hair Loss, and Aspiration with GLP1-Receptor Agonists and Other Diabetic Agents: A Real-World Pharmacovigilance Study. Cardiovasc Drugs Ther. 2025 Dec; 39(6):1331-1341.
-
Yukselen Z, Raju AKV, Kumar PA, Ujjawal A, Dasari M, Parajuli S, Nakhla M, Bansal K, Ganatra S, Dani SS. A Real-World Pharmacovigilance Study of FDA Adverse Event Reporting System (FAERS) for Mavacamten. Am J Cardiovasc Drugs. 2024 Nov; 24(6):791-799.
-
Bhanushali KB, Asnani HK, Nair A, Ganatra S, Dani SS. Pharmacovigilance study for SGLT 2 inhibitors- Safety review of real-world data & randomized clinical trials. Curr Probl Cardiol. 2024 Sep; 49(9):102664.
-
Kim YS, Brar S, D'Albo N, Dey A, Shah S, Ganatra S, Dani SS. Five Years of Sacubitril/Valsartan-a Safety Analysis of Randomized Clinical Trials and Real-World Pharmacovigilance. Cardiovasc Drugs Ther. 2022 10; 36(5):915-924.
-
Rawat BPS, Jagannatha A, Liu F, Yu H. Inferring ADR causality by predicting the Naranjo Score from Clinical Notes. AMIA Annu Symp Proc. 2020; 2020:1041-1049.
-
Liu F, Pradhan R, Druhl E, Freund E, Liu W, Sauer BC, Cunningham F, Gordon AJ, Peters CB, Yu H. Learning to detect and understand drug discontinuation events from clinical narratives. J Am Med Inform Assoc. 2019 10 01; 26(10):943-951.
-
Liu F, Jagannatha A, Yu H. Towards Drug Safety Surveillance and Pharmacovigilance: Current Progress in Detecting Medication and Adverse Drug Events from Electronic Health Records. Drug Saf. 2019 01; 42(1):95-97.
-
Bird ST, Gelperin K, Taylor L, Sahin L, Hammad H, Andrade SE, Mohamoud MA, Toh S, Hampp C. Enrollment and Retention in 34 United States Pregnancy Registries Contrasted with the Manufacturer's Capture of Spontaneous Reports for Exposed Pregnancies. Drug Saf. 2018 01; 41(1):87-94.